

Clinical Development of the Oral BTK Degradar UBX-303061 for Relapsed/Refractory B-Cell Malignancies

Ubix Therapeutics, Inc.



ONCOLOGY	Phase 1
Product Type	TPD
Indication	Relapsed/Refractory B-cell Malignancies
Target	BTK/HCK/LYN
MoA(Mechanism of Action)	Targeted Degradation of BTK, HCK, and LYN
Competitiveness	<p>Highlights of UBX-303061</p> <ul style="list-style-type: none"> • A first-in-class, orally bioavailable BTK/HCK/LYN degrader currently in global phase 1 dose-escalation trial for refractory/relapsed B cell malignancies. • Represents a strong market opportunity by:- Replacing \$10.4B BTK inhibitors by overcoming resistance mutations.- Expanding BTK-targeted therapy into the largely untapped \$7.5B DLBCL market. <p>Key points of differentiation</p> <ul style="list-style-type: none"> • Triple degradation mechanism achieving inactivation of both downstream and bypass pathways. • Complete tumor regression after oral dosing in both WT and C481S-BTK models. • Only BTK degrader showing broad mutation coverage and consistent efficacy across DLBCL subtypes, including those with poor prognostic genetics. • Favorable oral bioavailability, confirmed in both preclinical and clinical settings.
Development Stage	Phase 1
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.